Foreign Affairs

Trump’s 200% generic tariff threat would imperil Americans: Indian pharma

· 23 July 2026 · 2 min read
Trump’s 200% generic tariff threat would imperil Americans: Indian pharma

The Hindu has reported a new India-focused foreign affairs development: “Trump’s 200% generic tariff threat would imperil Americans: Indian pharma.” The publisher's feed describes the story as follows: Effective August 1, 2026, all generic drugs being brought into the United States will continue to have a tariff of zero per cent for a two-year period of time, after which the tariff will be raised to 100% for a one-year period of time, and 200% thereafter, said Donald Trump Intellectual Janata

Original reporting by The HinduRead the full story

Intellectual Janata displays only original summaries of externally sourced news and links readers to the original publisher.

#foreign-affairs#india

Related reading

IJP
News Brief
Foreign secretary Vikram Misri flags tariff move in talks with US undersecretary
Foreign Affairs·The Economic Times·25 Sep 2026

Foreign secretary Vikram Misri flags tariff move in talks with US undersecretary

Read full story →
IJP
News Brief
India and the plausible multilateralism of BRICS
Foreign Affairs·The Hindu·25 Sep 2026

India and the plausible multilateralism of BRICS

Read full story →
IJP
News Brief
CEA flags US friction, energy shocks, and missing AI play as India’s key near-term risks
Foreign Affairs·Mint·25 Sep 2026

CEA flags US friction, energy shocks, and missing AI play as India’s key near-term risks

Read full story →
IJP
News Brief
India, 17 others reserve rights to join Russia’s CBAM dispute with EU as third party at WTO
Foreign Affairs·The Economic Times·25 Sep 2026

India, 17 others reserve rights to join Russia’s CBAM dispute with EU as third party at WTO

Read full story →